Roy Herbst
MD, PhD
Ensign Professor of Medicine and Chief of Medical Oncology
👥Biography 个人简介
Roy Herbst led the ADAURA trial establishing three years of adjuvant osimertinib as standard of care for resected stage IB-IIIA EGFR-mutant NSCLC. His work demonstrated dramatic improvements in disease-free and overall survival, transforming post-operative management of early-stage EGFR-mutant lung cancer. He continues to investigate duration optimization and ctDNA-guided strategies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Roy Herbst 的研究动态
Follow Roy Herbst's research updates
留下邮箱，当我们发布与 Roy Herbst（Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment